Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder

Alene Kennedy‐Hendricks, Cameron Schilling, Alisa B. Busch, Elizabeth A. Stuart, Haiden A. Huskamp, Mark K. Meiselbach, Colleen L. Barry, Matthew D. EisenbergJournal of General Internal Medicine 2021 · DOI

Abstract

As High Deductible Health Plans (HDHPs) become more prevalent in the commercial insurance market, concerns have risen regarding their impact on essential treatments for Opioid Use Disorder (OUD). This study evaluates whether the transition to HDHPs disrupts the continuity of buprenorphine treatment. Using a difference-in-differences analysis of national claims data from 2007 to 2017, researchers found that while HDHP offers significantly increased out-of-pocket spending by approximately $99 per treatment episode, there was no significant reduction in treatment duration or retention milestones. These findings suggest that patients prioritize buprenorphine as a non-discretionary service, maintaining treatment despite increased financial strain.

Introduction

The United States is currently grappling with a severe opioid overdose crisis. Buprenorphine, a medication-assisted treatment (MAT), is considered the "gold standard" for managing OUD, as it significantly reduces mortality and illicit opioid use. However, the clinical effectiveness of buprenorphine is highly dependent on treatment continuity.

Simultaneously, the commercial insurance landscape has shifted toward High Deductible Health Plans (HDHPs)—plans characterized by lower premiums but higher out-of-pocket (OOP) costs before coverage begins. There is a significant concern that these financial barriers might lead patients to skip doses or discontinue life-saving treatment. This study investigates the impact of HDHP expansion on OUD treatment retention and the financial burden placed on patients.

Methods

The study utilized de-identified claims data from the OptumLabs® Data Warehouse, covering a national sample of commercial health insurance plans from 2007 to 2017. The final sample included 7,853 buprenorphine treatment episodes among enrollees aged 12–64 with an OUD diagnosis.

Researchers employed a Difference-in-Differences (DiD) analysis to compare a "treatment group" (enrollees whose employers began offering an HDHP) against a "comparison group" (enrollees whose employers never offered an HDHP). To minimize selection bias, an Intent-to-Treat (ITT) approach was used, focusing on the employer's offer of a plan rather than individual enrollment.

Statistical modeling included:

  • Tobit models for analyzing treatment days, accounting for right-censoring at 365 days.
  • Two-part models for out-of-pocket spending to handle the distribution of costs.
  • Fractional logit models for the proportion of months with concurrent behavioral therapy.

Results

Financial Impact

The introduction of an HDHP offer was associated with a statistically significant average increase of $98.73** (95% CI: $47.51, $141.95) in out-of-pocket spending on buprenorphine per treatment episode. For individuals who actually enrolled in an HDHP, the estimated increase in spending was approximately **$225 per episode.

Table 1: Estimated effect of HDHP offer on out-of-pocket spending per treatment episode.

Treatment Continuity and Retention

Despite the increased financial burden, the study found no significant change in the continuity of buprenorphine treatment. The estimated change in the number of treatment days was only 2.4 days, which was not statistically significant. Furthermore, there were no significant changes in the probability of patients reaching key retention milestones, such as 30, 90, 180, or 365 days of continuous treatment.

Table 2: Estimated effect of HDHP offer on buprenorphine treatment duration and retention milestones.

Additionally, the use of concurrent services, including behavioral therapy and OUD-related evaluation and management (E/M) visits, remained stable following the HDHP offer.

Discussion

The most significant insight from this research is the inelastic demand for buprenorphine among patients already in treatment. Unlike other "high-value" medical services that patients often reduce when faced with higher costs (such as preventive screenings), OUD treatment appears uniquely resilient. Patients likely perceive the risk of relapse or overdose as far more costly than the increased deductible.

However, this resilience may come at a cost. Patients might be cutting back on other essential health services or basic needs to afford their medication. Furthermore, this study only examined patients who had already initiated treatment; it does not account for individuals who may have been deterred from starting buprenorphine due to high upfront costs.

Conclusion

While HDHPs significantly increase the financial strain on patients treating Opioid Use Disorder, they do not appear to reduce the continuity of buprenorphine treatment for those already engaged in care. This suggests that patients prioritize this life-saving medication as an essential, non-discretionary service. Future policy and research should focus on ensuring that high deductibles do not create barriers to treatment initiation and exploring the broader impact of these costs on patient well-being.

Summary updated

BibTeX
@article{kennedyhendricks2021impact,
  author = {Alene Kennedy‐Hendricks and Cameron Schilling and Alisa B. Busch and Elizabeth A. Stuart and Haiden A. Huskamp and Mark K. Meiselbach and Colleen L. Barry and Matthew D. Eisenberg},
  title = {{Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder}},
  journal = {Journal of General Internal Medicine},
  year = {2021},
  doi = {10.1007/s11606-021-07094-9},
}
Figure